Clinical Trials Sponsored by Intergroupe Francophone du Myelome

Total 21 results

Intergroupe Francophone du Myelome

Unknown

Study in Myeloma Patients Newly Diagnosed Treated as an Induction With Velcade-Dex or Velcade (Bortezomib) Thalidomide Dexamethasone (VTD)

Multiple Myeloma

France, Belgium
Intergroupe Francophone du Myelome

Active, not recruiting

Evaluation of the Impact of the Update SMM Criteria on the Natural History of SMM to Establish New Recommendations. (CARRISMM)

Smoldering Multiple Myeloma

France, Belgium, Monaco
Intergroupe Francophone du Myelome

Completed

Study of Bendamustine, Velcade and Dexamethasone in the Treatment of Elderly Patients With Multiple Myeloma (BVD)

Multiple Myeloma

France
Intergroupe Francophone du Myelome

Recruiting

Diagnostic Performance of Spot Urine Sample for the Monoclonal Components Detection in Patients With Multiple Myeloma (RHUMM)

Multiple Myeloma

France
Intergroupe Francophone du Myelome

Terminated

Analysis of the Immune Parameters of COVID-19 Infection in Patients With Multiple Myeloma (Covimmunomm)

Covid19 | Multiple Myeloma

France
Intergroupe Francophone du Myelome

Completed

Pharmacogenomic Study in Myeloma Patients Treated With Melphalan-prednisone-thalidomide or Lenalidomide-dexamethasone

Myeloma

France
Intergroupe Francophone du Myelome

Completed

Assessment of Mobilization Cost for Multiple Myeloma Using 2 Different Mobilization Strategies (MOZOBIL)

Multiple Myeloma | Blood Stem Cell Transplant Failure

France
Rennes University Hospital
Intergroupe Francophone du Myelome

Terminated

Study of DNA Copy Numbers Variations and Gene Expression Profile of Bone Marrow Plasma Cells From MGUS and SMM. (GENOMGUS)

Monoclonal Gammopathy of Undetermined Significance | Smoldering Myeloma

France
University Hospital, Toulouse
Intergroupe Francophone du Myelome

Completed

Velcade®-Melphalan Association in Autologous Stem-Cell Transplantation (ASCT)

Multiple Myeloma

France
Intergroupe Francophone du Myelome
Janssen-Cilag Ltd.

Recruiting

Analysis of Effectiveness and Safety of Teclistamab in Relapsed and Refractory Multiple Myeloma Patients (TEC-CARE)

Multiple Myeloma

France
Poitiers University Hospital
Sanofi; Intergroupe Francophone du Myelome

Active, not recruiting

Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).

Multiple Myeloma | Myeloma

France
Intergroupe Francophone du Myelome
Bristol-Myers Squibb; Sanofi

Recruiting

Isatuximab Plus Pomalidomide and Dexamethasone Association for Patients With AL Amyloidosis Not in VGPR or Better After Any Previous Therapy (IsAMYP)

AL Amyloidosis

France
Poitiers University Hospital
Sanofi; Intergroupe Francophone du Myelome

Recruiting

Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma

Multiple Myeloma | Myeloma | Myeloma Multiple

France
Institut Curie
Celgene Corporation; Intergroupe Francophone du Myelome

Completed

A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial (PCD)

Multiple Myeloma | First Relapse

France
University Hospital, Toulouse
Celgene; Intergroupe Francophone du Myelome

Completed

Maintenance Therapy Using Lenalidomide in Myeloma (IFM2005-02)

Myeloma

France, Belgium, Switzerland
Intergroupe Francophone du Myelome
Bristol-Myers Squibb; Sanofi; Amgen

Active, not recruiting

MInimal Residual Disease Adapted Strategy (MIDAS)

Multiple Myeloma

France
Assistance Publique - Hôpitaux de Paris
Intergroupe Francophone du Myelome

Recruiting

Study of 4 Bone Turnover Markers in Patients With Multiple Myeloma Treated With Intravenous Bisphosphonate in Routine Care (AMBROBiMM)

Multiple Myeloma

France
University Hospital, Lille
Janssen, LP; Intergroupe Francophone du Myelome

Completed

Study of Daratumumab in Combination With Dexamethasone in Resistant or Refractory Multiple Myeloma (IFM2014-04)

Multiple Myeloma

France, Belgium
Poitiers University Hospital
Sanofi; Celgene; Amgen; Intergroupe Francophone du Myelome

Active, not recruiting

Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

France
Intergroupe Francophone du Myelome
Janssen Research & Development, LLC; HOVON - Dutch Haemato-Oncology Association

Active, not recruiting

A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma (Cassiopeia)

Multiple Myeloma

Netherlands, France, Belgium
Intergroupe Francophone du Myelome
Bristol-Myers Squibb; Takeda; University Hospital, Grenoble; Nantes University... and other collaborators

Terminated

IPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic (IFM2014-01)

Multiple Myeloma | Genetic Condition | Relapsed and Refractory Multiple Myeloma

France

3

Subscribe